The most comprehensive pan-cancer panel optimized and validated against certified reference materials for discovery of the most common genes, gene variants, detection of fusions/rearrangements, and splice variants powered by sophisticated algorithms to enable accurate analysis of TMB and MSI.
The Acutis TruSight™ Oncology 500 Tissue (TSO500), a next-generation sequencing (NGS) assay enables comprehensive pan-cancer genomic profiling (CGP) of solid tumor samples with more sensitivity, precision and reproducibility. The assay supports the identification of all relevant DNA and RNA variants implicated in various solid tumor types and accurately measures microsatellite instability (MSI) and tumor mutational burden (TMB).
Our assay is as twice as sensitive as other assays including Illumina's off-shelf protocol with SNV/Indel VAF LOD of 2% vs 5% in other assays:
- 1.94 Mb of DNA with sophisticated algorithms enabling accurate analysis of TMB and MSI
- The most comprehensive cancer panel to detect fusions/rearrangements and splice variants in 55 genes at the RNA level
- Gene fusions/rearrangements is tested in RNA instead of DNA allowing for detection of any possible partner genes
- CNVs in 59 of the most common cancer genes
- Run on DNA and RNA co-extracted from FFPE from 5 sections
